Charles River Laboratories International, Inc. $CRL Stock Sold by Keybank National Association OH

Keybank National Association OH decreased its holdings in Charles River Laboratories International, Inc. (NYSE:CRL) by 27.3% in the 3rd quarter, HoldingsChannel reports. The firm owned 5,822 shares of the medical research company’s stock after selling 2,181 shares during the quarter. Keybank National Association OH’s holdings in Charles River Laboratories International were worth $1,718,000 at the end of the most recent reporting period.

Other institutional investors have also recently bought and sold shares of the company. Handelsbanken Fonder AB boosted its stake in Charles River Laboratories International by 36.9% in the second quarter. Handelsbanken Fonder AB now owns 19,306 shares of the medical research company’s stock worth $4,378,000 after purchasing an additional 5,200 shares in the last quarter. Avidity Partners Management LP acquired a new stake in shares of Charles River Laboratories International in the first quarter valued at $1,670,000. Evergreen Capital Management LLC acquired a new stake in shares of Charles River Laboratories International in the third quarter valued at $2,621,000. Quantitative Investment Management LLC acquired a new stake in shares of Charles River Laboratories International in the second quarter valued at $1,360,000. Finally, Madison Asset Management LLC bought a new position in shares of Charles River Laboratories International in the second quarter valued at about $3,805,000. Institutional investors own 98.91% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on CRL. Wall Street Zen raised Charles River Laboratories International from a “hold” rating to a “buy” rating in a report on Saturday, November 7th. Argus set a $330.00 price objective on shares of Charles River Laboratories International in a report on Thursday, September 17th. CLSA cut shares of Charles River Laboratories International from an “outperform” rating to a “hold” rating and set a $219.00 price objective for the company. in a research report on Monday, July 20th. Royal Bank Of Canada raised their price objective on shares of Charles River Laboratories International from $322.00 to $352.00 and gave the company an “outperform” rating in a research report on Thursday, November 5th. Finally, JPMorgan Chase & Co. raised shares of Charles River Laboratories International from a “neutral” rating to an “overweight” rating and boosted their target price for the stock from $180.00 to $310.00 in a research note on Thursday, August 6th. Thirteen analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Charles River Laboratories International has an average rating of “Moderate Buy” and a consensus price target of $311.67.

Charles River Laboratories International Trading Down 0.7%

CRL traded down $2.54 during mid-day trading on Friday, reaching $338.27. The stock had a trading volume of 838,240 shares, compared to its average volume of 1,294,316. The stock has a market capitalization of $16.21 billion, a P/E ratio of 371.73, a P/E/G ratio of 3.08 and a beta of 1.36. The company has a debt-to-equity ratio of 0.76, a quick ratio of 1.12 and a current ratio of 1.41. The firm’s fifty day simple moving average is $311.21 and its two-hundred day simple moving average is $228.24. Charles River Laboratories International, Inc. has a 52 week low of $146.20 and a 52 week high of $379.63.

Charles River Laboratories International (NYSE:CRL) last released its earnings results on Wednesday, November 4th. The medical research company reported $3.09 EPS for the quarter, beating the consensus estimate of $2.97 by $0.12. The company had revenue of $982.73 million during the quarter, compared to analysts’ expectations of $960.36 million. Charles River Laboratories International had a return on equity of 16.95% and a net margin of 1.01%. The business’s revenue for the quarter was down 2.2% on a year-over-year basis. During the same period last year, the firm earned $2.43 EPS. On average, equities analysts predict that Charles River Laboratories International, Inc. will post 11.45 EPS for the current year.

Insider Activity

In related news, Director James Foster sold 33,561 shares of Charles River Laboratories International stock in a transaction dated Tuesday, August 25th. The stock was sold at an average price of $300.00, for a total value of $10,068,300.00. Following the completion of the sale, the director directly owned 31,596 shares in the company, valued at $9,478,800. This trade represents a 51.51% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Shannon M. Parisotto sold 2,156 shares of the business’s stock in a transaction dated Wednesday, October 21st. The stock was sold at an average price of $344.41, for a total value of $742,547.96. Following the sale, the executive vice president directly owned 4,807 shares of the company’s stock, valued at $1,655,578.87. This represents a 30.96% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 63,352 shares of company stock valued at $20,291,281 over the last 90 days. 1.30% of the stock is owned by company insiders.

Charles River Laboratories International Company Profile

Charles River Laboratories International is a contract research organization that supports pharmaceutical and biotechnology companies, as well as academic and government researchers, in developing medicines and advancing scientific research. Its services span the drug development process, from early discovery and preclinical research to manufacturing support. The company’s offerings include research models and related services, drug discovery and safety assessment, and manufacturing solutions. These may include laboratory animal models, laboratory testing, bioanalysis, and support for the production of products used in the development of pharmaceuticals and biologics.